Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 25, 2009

Lonza to Manufacture Micromet’s Blinatumomab BiTE Antibody

  • Lonza is to carry out process development and manufacture of Micromet’s clinical-stage CD19-targeting BiTE antibody, blinatumomab (MT103). Under terms of the deal Lonza will manufacture blinatumomab for clinical trials, develop a commercial-scale process, and supply commercial quantities of the drug if requested.

    Blinatumomab is a lymphoma-directed, recombinant bispecific single-chain antibody generated using Micromet's BiTE® antibody technology. The candidate is currently undergoing Phase II trials in acute lymphoblastic leukemia, and a Phase I trial in non-Hodgkin lymphoma.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »